Expression of Notch-1 and its clinical significance in different histological subtypes of human lung adenocarcinoma

Journal of Experimental & Clinical Cancer Research

Longbang Chen¹  Rui Wang¹  Bo Yu²  Biao Liu²  Haizhu Song¹  Jiayuan Huang¹ 

[1] Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, 315 Zhongshan East Road, Nanjing, Jiangsu 210002, PR China;Department of Pathology, Jinling Hospital, School of Medicine, Nanjing University, 305 Zhongshan East Road, Nanjing 210002, China

关键词: Prognosis;    Histological subtypes;    Immunohistochemistry;    Notch-1;    Lung adenocarcinoma;   

Others  :  814332
DOI  :  10.1186/1756-9966-32-84

 received in 2013-06-29, accepted in 2013-10-24,  发布年份 2013

【 摘 要 】

Background

According to the International Multidisciplinary Classification of Lung Adenocarcinoma (LAD) by International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) in 2011, the diagnosis of LAD is changing from simple morphology into a comprehensive multidisciplinary classification. The aim of this study is to detect the expression of Notch-1 and analyze its clinicopathological or prognostic significance in different histological subtypes of Lung Adenocarcinomas (LADs).

Methods

Western blot and Semi-quantitative Reverse transcription-polymerase chain reaction (RT-PCR) assays, as well as immunohisitochemistry, were performed to detect the expression of Notch-1 in LAD cells and tissue samples. Kaplan-Meier and multivariate Cox regression analyses were performed to evaluate the correlation of Notch-1 expression with clinicopathological factors and prognosis of LAD patients.

Results

The expression level of Notch-1 protein in LAD cell lines or tissues was significantly lower than that in normal human bronchial epithelial cell line (16HBE) or nontumor tissues (P < 0.05). By statistical analyses, it was observed that negative Notch-1 expression was significantly associated with advanced clinical stage (P = 0.001) and lymph node metastasis (P = 0.026) in LAD patients. Also, the recurrence rate of Notch-1-positive group was higher than the Notch-1-negative group (P = 0.001), and patients with positive Notch-1 expression have a prolonged progression of overall survival (P = 0.033). More interestingly, the expression of Notch-1 protein was often observed to be negative in solid predominant adenocarcinoma (SPA) tissues, but highly expressed in papillary predominant adenocarcinoma (PPA) and micropapillary predominant adenocarcinoma (MPA) tissues. Kaplan-Meier survival analysis showed that patients with positive Notch-1 expression had a prolonged progression of overall survival compared with those with negative Notch-1 expression (P = 0.033). The median survival time of Notch-1-positive or negative patients was 64.6 months (95% CI: 31.497-97.703 months) or 36.0 months (95% CI: 12.132-59.868 months).

Conclusions

Notch-1 could be used as a predictable biomarker to be detected in different pathological and histological subtypes in LAD for diagnosis or prognosis.

【 授权许可】

   
2013 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA: A cancer journal for clinicians 2011, 61(2):69-90.
• [2]Sánchez-Mora N, Presmanes MC, Monroy V, Moreno N, Lara-Martínez JM, Aladro MH, Álvarez-Fernández E: Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. Human pathology 2008, 39(3):324-330.
• [3]Kauffmann M, Kruger T, Aebert H: Surgery on extracorporeal circulation in early and advanced non-small cell lung cancer. Thorac Cardiovasc Surg 2013, 61(2):103-108.
• [4]Xu C, Gui Q, Chen W, Wu L, Sun W, Zhang N, Xu Q, Wang J, Fu X: Small interference RNA targeting tissue factor inhibits human lung adenocarcinoma growth in vitro and in vivo. J Exp Clin Cancer Res 2011, 30:63. BioMed Central Full Text
• [5]Ma Q, Li P, Xu M, Yin J, Su Z, Li W, Zhang J: Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance. J Exp Clin Cancer Res 2012, 31:99. BioMed Central Full Text
• [6]Karamboulas C, Ailles L: Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta 2013, 1830(2):2481-2495.
• [7]Zhou W, Fu X, Zhang L, Zhang J, Huang X, Lu X, Shen L, Liu B, Liu J, Luo H: The AKT1/NF-kappaB/Notch1/PTEN axis has an important role in chemoresistance of gastric cancer cells. Cell Death & Disease 2013, 4(10):e847.
• [8]Yu XM, Phan T, Patel PN, Jaskula‒Sztul R, Chen H: Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo. Cancer 2013, 119(4):774-781.
• [9]Donnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM: Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer 2010, 116(24):5676-5685.
• [10]Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, et al.: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6(2):244-285.
• [11]Krikelis D, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Petrakis D, Stoyianni A, Golfinopoulos V, Cervantes A, Ciuleanu T, Fountzilas G, Malamou-Mitsi V, Pavlidis N: Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. Clin Exp Metastasis 2012, 29(6):603-614.
• [12]Rami-Porta R, Crowley JJ, Goldstraw P: Review The Revised TNM Staging System for Lung Cancer. Ann Thorac Cardiovasc Surg 2009, 15(1):5.
• [13]Jundt F, Acikgoz O, Kwon SH, Schwarzer R, Anagnostopoulos I, Wiesner B, Mathas S, Hummel M, Stein H, Reichardt HM, Dörken B: Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia 2008, 22(8):1587-1594.
• [14]Zhang J, Ma D, Ye J, Zang S, Lu F, Yang M, Qu X, Sun X, Ji C: Prognostic impact of delta-like ligand 4 and Notch1 in acute myeloid leukemia. Oncol Rep 2012, 28(4):1503-1511.
• [15]Zhang X, Chen T, Zhang J, Mao Q, Li S, Xiong W, Qiu Y, Xie Q, Ge J: Notch1 Promotes Glioma Cell Migration and Invasion by Stimulating β‒catenin and NF‒κB Signaling via AKT Activation. Cancer Sci 2012, 103(2):181-190.
• [16]Li XJ, Ji MH, Zhong SL, Zha QB, Xu JJ, Zhao JH, Tang JH: MicroRNA-34a Modulates Chemosensitivity of Breast Cancer Cells to Adriamycin by Targeting Notch1. Arch Med Res 2012, 43(7):514-521.
• [17]Xie M, Liu M, He CS: SIRT1 regulates endothelial Notch signaling in lung cancer. PLoS One 2012, 7(9):e45331.
• [18]Guo Z, Jin X, Jia H: Inhibition of ADAM-17 more effectively down-regulates the Notch pathway than that of gamma-secretase in renal carcinoma. J Exp Clin Cancer Res 2013, 32:26. BioMed Central Full Text
• [19]Su C, Chen Z, Luo H, Su Y, Liu W, Cai L, Wang T, Lei Y, Zhong B: Different patterns of NF-kappaB and Notch1 signaling contribute to tumor-induced lymphangiogenesis of esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2011, 30:85. BioMed Central Full Text
• [20]Kim A, Kim EY, Cho EN, Kim HJ, Kim SK, Chang J, Ahn CM, Chang YS: Notch1 destabilizes the adherens junction complex through upregulation of the Snail family of E-cadherin repressors in non-small cell lung cancer. Oncology reports 2013, 30(3):1423-1429.
• [21]Zheng Q, Qin H, Zhang H, Li J, Hou L, Wang H, Zhang X, Zhang S, Feng L, Liang Y, Han H, Yi D: Notch signaling inhibits growth of the human lung adenocarcinoma cell line A549. Oncol Rep 2007, 17(4):847-852.
• [22]Chen Y, Li D, Liu H, Xu H, Zheng H, Qian F, Li W, Zhao C, Wang Z, Wang X: Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. Cancer biology & therapy 2011, 11(1):14-21.
• [23]Chen Y, De Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L, Bocchetta M: Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer research 2007, 67(17):7954-7959.
• [24]Xia W, Wong ST, Hanlon E, Morin P: γ-Secretase Modulator in Alzheimer's Disease: Shifting the End. J Alzheimers Dis 2012, 31(4):685-696.
• [25]Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H: A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer 2012, 48(7):997-1003.
• [26]Licciulli S, Avila JL, Hanlon L, Troutman S, Cesaroni M, Kota S, Keith B, Simon MC, Puré E, Radtke F: Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53. Cancer research 2013, 73(19):5974-5984.
• [27]Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, Dorfman D, Pinkus G, Weigert O, Hornick JL: Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS One 2013, 8(6):e67306.